SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+1.14%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.7B
AUM Growth
+$2.7B
(-3.1%)
Cap. Flow
-$18.7M
Cap. Flow
% of AUM
-0.69%
Top 10 Holdings %
Top 10 Hldgs %
42.98%
Holding
115
New
16
Increased
19
Reduced
24
Closed
18
Top Buys
| 1 |
Legend Biotech
LEGN
|
$114M |
| 2 |
Immatics
IMTX
|
$36M |
| 3 |
Coca-Cola
KO
|
$34.2M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
$32.3M |
| 5 |
Boeing
BA
|
$27.5M |
Top Sells
| 1 |
Apple
AAPL
|
$78.3M |
| 2 |
Arcellx
ACLX
|
$57.6M |
| 3 |
Royalty Pharma
RPRX
|
$52.8M |
| 4 |
AT&T
T
|
$50.3M |
| 5 |
Kezar Life Sciences
KZR
|
$43.3M |
Sector Composition
| 1 | Healthcare | 60.76% |
| 2 | Consumer Discretionary | 9.71% |
| 3 | Technology | 9.58% |
| 4 | Financials | 6.08% |
| 5 | Communication Services | 5.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biohaven
BHVN
$1.63B
| $210M | 7.15% | 5,620,271 +421,052 | +8% | +$15.7M |
|
2
Arcutis Biotherapeutics
ARQT
$1.86B
| $159M | 5.41% | 11,399,138 +677,627 | +6% | +$9.44M |
|
|
ITCI
3
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $120M | 4.1% | 1,439,026 | – | – |
|
|
4
Legend Biotech
LEGN
$6.41B
| $114M | 3.88% | +3,496,234 | New | +$114M |
|
5
Benitec Biopharma
BNTC
$348M
| $113M | 3.86% | 8,960,009 +130,956 | +1% | +$1.65M |
|
6
Insmed
INSM
$28.8B
| $111M | 3.79% | 1,611,561 -24,148 | -1% | -$1.67M |
|
7
Meta Platforms (Facebook)
META
$1.86T
| $99.7M | 3.4% | 170,338 +1,850 | +1% | +$1.08M |
|
8
89bio
ETNB
$1.34B
| $79.8M | 2.72% | 10,202,696 +2,211,052 | +28% | +$17.3M |
|
9
Amazon
AMZN
$2.44T
| $77.1M | 2.63% | 351,281 -788 | -0.2% | -$173K |
|
10
Apollo Global Management
APO
$77.9B
| $76.7M | 2.61% | 464,140 -910 | -0.2% | -$150K |
|
|
11
Coca-Cola
KO
$297B
| $70.8M | 2.41% | 1,137,853 +548,941 | +93% | +$34.2M |
|
12
TSMC
TSM
$1.2T
| $68.3M | 2.33% | 345,912 -2,830 | -0.8% | -$559K |
|
13
Tesla
TSLA
$1.08T
| $66.1M | 2.25% | 163,630 -30,212 | -16% | -$12.2M |
|
14
ArriVent BioPharma
AVBP
$776M
| $59.8M | 2.04% | 2,246,000 +400,838 | +22% | +$10.7M |
|
15
EyePoint Pharmaceuticals
EYPT
$797M
| $50.5M | 1.72% | 6,783,091 +1,607,268 | +31% | +$12M |
|
16
Microsoft
MSFT
$3.77T
| $49.9M | 1.7% | 118,397 +21,871 | +23% | +$9.22M |
|
17
Ultragenyx Pharmaceutical
RARE
$2.89B
| $48.4M | 1.65% | 1,151,314 | – | – |
|
18
Starbucks
SBUX
$100B
| $47M | 1.6% | 514,922 -35,387 | -6% | -$3.23M |
|
19
Capital One
COF
$145B
| $44.9M | 1.53% | 251,642 +16,042 | +7% | +$2.86M |
|
20
Kura Oncology
KURA
$686M
| $44.2M | 1.51% | 5,076,448 -2,576,334 | -34% | -$22.4M |
|
21
Ferguson
FERG
$46.4B
| $42.6M | 1.45% | 245,530 +20,320 | +9% | +$3.53M |
|
22
Goldman Sachs
GS
$226B
| $42.5M | 1.45% | 74,198 -34,110 | -31% | -$19.5M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $41.6M | 1.42% | 4,913,012 +701,007 | +17% | +$5.94M |
|
24
Advanced Micro Devices
AMD
$264B
| $40.8M | 1.39% | 337,415 -9,160 | -3% | -$1.11M |
|
25
CRH
CRH
$75.9B
| $40.4M | 1.38% | 436,394 -102,500 | -19% | -$9.48M |
|